1. Home
  2. BRN vs NRSN Comparison

BRN vs NRSN Comparison

Compare BRN & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barnwell Industries Inc.

BRN

Barnwell Industries Inc.

HOLD

Current Price

$1.18

Market Cap

15.0M

Sector

Energy

ML Signal

HOLD

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$0.74

Market Cap

28.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRN
NRSN
Founded
1956
2017
Country
United States
Israel
Employees
N/A
15
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.0M
28.4M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
BRN
NRSN
Price
$1.18
$0.74
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
398.4K
171.5K
Earning Date
05-14-2026
03-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,697,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$0.63
52 Week High
$2.28
$2.60

Technical Indicators

Market Signals
Indicator
BRN
NRSN
Relative Strength Index (RSI) 54.94 41.04
Support Level $1.06 $0.68
Resistance Level $1.28 $1.30
Average True Range (ATR) 0.08 0.08
MACD 0.00 -0.00
Stochastic Oscillator 78.87 34.24

Price Performance

Historical Comparison
BRN
NRSN

About BRN Barnwell Industries Inc.

Barnwell Industries Inc is an oil and gas company engaged in the acquisition, development, production, and sale of crude oil and natural gas. The Company operates through two segments: the Oil and Natural Gas segment, which focuses on oil and natural gas development, production, acquisitions, and sales in the United States and Canada; and the Land Investment segment, which owns leasehold land interests in Hawaii. The Company generates the majority of its revenue from the Oil and Natural Gas segment. The company operates in two geographic regions, the United States and Canada, with Canada contributing the majority of revenue.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: